- Home
- HKPD vs APVO Comparison
HKPD vs APVO Comparison
Compare HKPD & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKPD
- APVO
- Stock Information
- Founded
- HKPD 2016
- APVO 2016
- Country
- HKPD Hong Kong
- APVO United States
- Employees
- HKPD N/A
- APVO N/A
- Industry
- HKPD Other Pharmaceuticals
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- HKPD Health Care
- APVO Health Care
- Exchange
- HKPD Nasdaq
- APVO Nasdaq
- Market Cap
- HKPD 20.9M
- APVO 21.7M
- IPO Year
- HKPD 2025
- APVO N/A
- Fundamental
- Price
- HKPD $1.19
- APVO $1.48
- Analyst Decision
- HKPD
- APVO
- Analyst Count
- HKPD 0
- APVO 0
- Target Price
- HKPD N/A
- APVO N/A
- AVG Volume (30 Days)
- HKPD 184.2K
- APVO 989.6K
- Earning Date
- HKPD 08-14-2025
- APVO 11-06-2025
- Dividend Yield
- HKPD N/A
- APVO N/A
- EPS Growth
- HKPD N/A
- APVO N/A
- EPS
- HKPD N/A
- APVO N/A
- Revenue
- HKPD $20,313,818.00
- APVO N/A
- Revenue This Year
- HKPD N/A
- APVO N/A
- Revenue Next Year
- HKPD N/A
- APVO N/A
- P/E Ratio
- HKPD N/A
- APVO N/A
- Revenue Growth
- HKPD 21.72
- APVO N/A
- 52 Week Low
- HKPD $0.81
- APVO $1.32
- 52 Week High
- HKPD $3.79
- APVO $298.00
- Technical
- Relative Strength Index (RSI)
- HKPD 44.83
- APVO 46.10
- Support Level
- HKPD $1.17
- APVO $1.40
- Resistance Level
- HKPD $1.40
- APVO $1.53
- Average True Range (ATR)
- HKPD 0.14
- APVO 0.08
- MACD
- HKPD -0.01
- APVO 0.01
- Stochastic Oscillator
- HKPD 14.04
- APVO 38.64
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.